Little Resistance to Linezolid in the U.S. After 15 Years of Use

Linezolid resistance among a representative sample of gram-positive pathogens was only 0.22%.

Linezolid, an oxazolidinone antibiotic agent licensed in the U.S. in April 2000, exerts its antibacterial activity by binding to bacterial ribosomes, thus inhibiting protein synthesis. Because emerging resistance is a concern for all antibiotics, an industry-sponsored resistance surveillance program was initiated in 2004 and updated annually thereafter.

The most recent sample, collected during 2014 from 60 U.S. medical centers in 36 states, comprised 6865 gram-positive pathogens: Staphylococcus aureus (1641 oxacillin-susceptible, 1465 methicillin-resistant Staphylococcus aureus [MRSA]), coagulase-negative staphylococci (CoNS; 797), enterococci (855), Streptococcus pneumoniae (874), and other streptococci (1233). Isolates were primarily from …

Reviewing Author

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Little Resistance to Linezolid in the U.S. After 15 Years of Use

Topics

Reviewing Author